These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34130477)

  • 1. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention.
    Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Witzenbichler B; Gewalt S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
    Circ Cardiovasc Interv; 2021 Jul; 14(7):e010565. PubMed ID: 34130477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
    Claassens DMF; Bergmeijer TO; Vos GJA; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Mahmoodi BK; Deneer VHM; Ten Berg JM
    Circ Cardiovasc Interv; 2021 Apr; 14(4):e009434. PubMed ID: 33722066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk.
    Lahu S; Presch A; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Hapfelmeier A; Kufner S; Rifatov N; Sager HB; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Neumann FJ; Sibbing D; Angiolillo DJ; Kastrati A; Cassese S
    Circ Cardiovasc Interv; 2022 Oct; 15(10):e012204. PubMed ID: 36256695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of body size on platelet function in patients with acute coronary syndrome on dual antiplatelet therapy.
    Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
    Vascul Pharmacol; 2022 Oct; 146():107089. PubMed ID: 35870771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
    Wöhrle J; Seeger J; Lahu S; Mayer K; Bernlochner I; Gewalt S; Menichelli M; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Kufner S; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Ndrepepa G
    JACC Cardiovasc Interv; 2021 Sep; 14(17):1857-1866. PubMed ID: 34446390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial.
    Sulzgruber P; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):273-274. PubMed ID: 31865384
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry.
    Al Raisi S; Protty M; Raposeiras-Roubín S; D'Ascenzo F; Abu-Assi E; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores-Blanco P; Varbella F; Cespón-Fernández M; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Cequier Á; Gaita F; Alexopoulos D; Valgimigli M; Íñiguez-Romo A; Kinnaird T
    Minerva Cardiol Angiol; 2021 Aug; 69(4):408-416. PubMed ID: 34137238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy.
    Hemetsberger R; Richardt G; Lahu S; Valina C; Menichelli M; Abdelghani M; Wöhrle J; Toelg R; Witzenbichler B; Mankerious N; Liebetrau C; Bernlochner I; Hamm CW; Allali A; Joner M; Fusaro M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Schüpke S; Laugwitz KL; Schunkert H; Neumann FJ; Kastrati A; Cassese S
    Cardiovasc Revasc Med; 2022 Aug; 41():122-128. PubMed ID: 35045943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes.
    Lahu S; Ndrepepa G; Gewalt S; Schüpke S; Pellegrini C; Bernlochner I; Aytekin A; Neumann FJ; Menichelli M; Richardt G; Cassese S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Mayer K
    Int J Cardiol; 2021 Sep; 338():8-13. PubMed ID: 34126130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel-related hepatotoxicity.
    Dogan Z; Yurtdas M; Bektasoglu G
    J Pak Med Assoc; 2022 Nov; 72(11):2295-2297. PubMed ID: 37013306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
    Lee SJ; Lee YJ; Kim BK; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Circ Cardiovasc Interv; 2021 Aug; 14(8):e010812. PubMed ID: 34281363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.
    Dayoub EJ; Nathan AS; Khatana SAM; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Groeneveld PW; Giri J
    Circ Cardiovasc Interv; 2019 Jan; 12(1):e007434. PubMed ID: 30608869
    [No Abstract]   [Full Text] [Related]  

  • 18. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial.
    Gewalt S; Lahu S; Ndrepepa G; Pellegrini C; Bernlochner I; Neumann FJ; Menichelli M; Morath T; Witzenbichler B; Wöhrle J; Hoppe K; Richardt G; Laugwitz KL; Schunkert H; Kastrati A; Schüpke S; Mayer K
    J Atheroscler Thromb; 2022 May; 29(5):747-761. PubMed ID: 33867409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.